Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SD-101 with checkpoint blockade in liver cancer
NCT05220722Phase 2Terminated
- Sponsor
- TriSalus Life Sciences
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of nelitolimod in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), sponsored by TriSalus Life Sciences. Started Mar 2022; status: terminated.
02
Drugs
nelitolimod
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05220722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05220722.